FUJIREBIO-EUROPE
19.11.2021 08:04:08 CET | Business Wire | Press release
Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology biomarkers NPTX2 and sTREM2 on the well-established INNOTEST platform. These are the first official product launches after the collaboration agreement announced in September 2020 between Fujirebio Europe and ADx NeuroSciences.
Both new tests are solid-phase enzyme immunoassays and are for research use only. INNOTEST NPTX2 is intended for the quantitative determination of neuronal pentraxin-2 (NPTX2) in human CSF, and INNOTEST sTREM2 is intended for the quantitative determination of soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) in human CSF.
“Fujirebio pioneered Alzheimer’s disease (AD) testing for the first time more than 25 years ago, when we launched the world’s first CSF based (INNOTEST) assay. And it was another milestone for AD testing when Fujirebio brought all four main Tau and β-amyloid biomarkers to the fully automated LUMIPULSE® G platform in 2018”, said Christiaan De Wilde, CEO of Fujirebio Europe. “We are confident that by bringing NPTX2 and sTREM2, two very promising biomarkers, on the easy-to-use INNOTEST platform, we can help researchers gain valuable insights in the fight for an even earlier diagnosis of AD patients”.
The importance of new biomarkers for Alzheimer’s disease research
Having well characterized assays for these novel markers gives researchers the required tools to further elucidate the pathogenesis of AD and support the AD drug development pipeline1 . In recent years, neuroinflammation has been acknowledged as a critical component in the development of the disease, and synaptic dysfunction is considered a core feature of AD early in the disease course2 . NPTX2 and sTREM2 are linked to synaptic dysfunction and neuroinflammation, respectively. Drug targets related to other (non-amyloid, non-Tau) mechanisms are gaining more interest.
About Fujirebio
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
About ADx NeuroSciences
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production and worldwide commercialization of novel biomarkers in the field of Alzheimer’s and Parkinson’s disease.
References
- Cummings J. et al. , Alzheimers Dement (N Y) 2021; 7:e12179.
- Del Prete E. et al. , J Pers Med 2020; 10:221.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 08:00:00 CET | Press release
Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting20.3.2026 06:55:00 CET | Press release
The Board of Directors proposes a dividend of 0.35 CHF per registered share Harry Kirsch proposed as new independent member of the Board of Directors Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board members from L’Oréal Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST. Dividend proposal The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contributions and, in accordance with applicable tax regulations, will be free from Swiss withholding tax. Proposed elections to the Board of Directors of Galderma Group AG As previously announced, and in connection with L’Oréal’s increased investment in Galderma, the Board members representi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom